Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Huizhou Comvikin Biotechnology is a synthetic biology company that specializes in the production of high-purity biosynthetic ingredients through a proprietary enzymatic synthesis platform. Founded in 2019 and headquartered in Shenzhen, China, the company is the world's largest manufacturer of Ascorbyl Palmitate, a fat-soluble antioxidant used in the food, cosmetic, and pharmaceutical industries. Comvikin's "zero-emission" technology platform allows for environmentally friendly production of various esters and vitamins, including phytosterol esters and vitamin A palmitate. The company operates a large-scale manufacturing base in Huizhou and maintains research collaborations with prestigious institutions like Tsinghua University. Comvikin is backed by prominent investors, including CDH Investments and the Moutai Technology Innovation Fund, to support its global expansion and R&D efforts.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Comvikin.